Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Orthofix ( (OFIX) ) has shared an update.
On June 18, 2025, Orthofix Medical Inc. held its annual meeting of shareholders, where a quorum was achieved with 35,364,307 shares present. Key decisions included the election of the board of directors for a one-year term, approval of executive compensation, and ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year 2025. Additionally, Vickie L. Capps was appointed to the Audit and Finance Committee and the Compensation and Talent Development Committee, effective immediately.
The most recent analyst rating on (OFIX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Orthofix stock, see the OFIX Stock Forecast page.
Spark’s Take on OFIX Stock
According to Spark, TipRanks’ AI Analyst, OFIX is a Neutral.
Orthofix’s stock score is primarily impacted by financial struggles, including profitability and cash flow issues, along with bearish technical signals. Positive earnings call insights provide some stability, but overall risks dominate.
To see Spark’s full report on OFIX stock, click here.
More about Orthofix
Orthofix Medical Inc. operates in the medical device industry, focusing on products and services related to orthopedic solutions. The company is involved in developing and delivering innovative medical devices to improve patient mobility and quality of life.
Average Trading Volume: 387,850
Technical Sentiment Signal: Sell
Current Market Cap: $405.5M
Learn more about OFIX stock on TipRanks’ Stock Analysis page.